Quote:

---

Just like Ohm20 says, they don't understand what they are looking at, because they don't understand Leronlimab's mechanism of action.

---

During the conference call Dr. Hansen said something about further studying the mechanism of action. Dr. Recknor was doing that in the NASH trial by getting the results for a broad array of cytokines, I say hallelujah to both. Prior the company had only a crude understanding of what leronlimab was doing, You need to get the fundamentals as a building block to understand what avenues to pursue and how best to design trials.